A subscription to JoVE is required to view this content. Sign in or start your free trial.
The present protocol describes a standardized resection of brain tumors in rodents through a minimally invasive approach with an integrated tissue preservation system. This technique has implications for accurately mirroring the standard of care in rodent and other animal models.
The present protocol describes a standardized paradigm for rodent brain tumor resection and tissue preservation. In clinical practice, maximal tumor resection is the standard-of-care treatment for most brain tumors. However, most currently available preclinical brain tumor models either do not include resection, or utilize surgical resection models that are time-consuming and lead to significant postoperative morbidity, mortality, or experimental variability. In addition, performing resection in rodents can be daunting for several reasons, including a lack of clinically comparable surgical tools or protocols and the absence of an established platform for standardized tissue collection. This protocol highlights the use of a multi-functional, non-ablative resection device and an integrated tissue preservation system adapted from the clinical version of the device. The device applied in the present study combines tunable suction and a cylindrical blade at the aperture to precisely probe, cut, and suction tissue. The minimally invasive resection device performs its functions via the same burr hole used for the initial tumor implantation. This approach minimizes alterations to regional anatomy during biopsy or resection surgeries and reduces the risk of significant blood loss. These factors significantly reduced the operative time (<2 min/animal), improved postoperative animal survival, lower variability in experimental groups, and result in high viability of resected tissues and cells for future analyses. This process is facilitated by a blade speed of ~1,400 cycles/min, which allows the harvesting of tissues into a sterile closed system that can be filled with a physiologic solution of choice. Given the emerging importance of studying and accurately modeling the impact of surgery, preservation and rigorous comparative analysis of regionalized tumor resection specimens, and intra-cavity-delivered therapeutics, this unique protocol will expand opportunities to explore unanswered questions about perioperative management and therapeutic discovery for brain tumor patients.
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. Despite recent advances in neurosurgery, targeted drug development, and radiation therapy, the 5-year survival rate for GBM patients is less than 5%, a statistic that has not significantly improved in over three decades1. Hence, there is a need for more effective treatment strategies.
To develop new therapies, it is becoming increasingly apparent that investigational protocols need to (1) utilize translatable preclinical models that accurately recapitulate the tumor heterogeneity and microenvironment, (2) mirror the standard therapeut....
All animal studies were approved by the University of Maryland and the Johns Hopkins University Institutional Animal Care and Use Committee. C57BL/6 female mice, 6-8 weeks of age, were used for the present study. The mice were obtained from commercial sources (see Table of Materials). All Biosafety Level 2 (BSL-2) regulations were followed, including the usage of masks, gloves, and gowns.
1. Initial intracranial tumor implantation
Surgical resection using the MIRS results in a significant decrease in the tumor burden
In the group with a smaller tumor burden, the mean baseline bioluminescent signal was 5.5e+006 photons/s ± 0.2e+006 in the subgroup that underwent resection. Following resection, the mean bioluminescent signal decreased to 3.09e+006 photons/s ± 0.3e+006, (p <0.0001, Mann-Whitney test)9 (Figure 2). The bioluminescen.......
Tumor resection is a cornerstone of neurosurgical oncology treatment plans for both low-grade and high-grade brain tumors. Cytoreduction and debulking of the tumor correlate with improved neurological function and overall survival in patients with brain tumors1,2,5,6. Although protocols for surgical resection have been previously described in rodent models, these protocols have suffered from se.......
BT has research funding from NIH and is a co-owner for Accelerating Combination Therapies*, and Ashvattha Therapeutics Inc. has licensed one of her patents. GW has NIH funding (R01NS107813). HB is a paid consultant to Insightec and chairman of the company's Medical Advisory Board. This arrangement has been reviewed and approved by Johns Hopkins University following its conflict-of-interest policies. HB has research funding from NIH, Johns Hopkins University, and philanthropy and is a consultant for CraniUS, Candel Therepeutics, Inc., Accelerating Combination Therapies*, Catalio Nexus Fund II, LLC*, LikeMinds, Inc*, Galen Robotics, Inc.* and Nurami Medical*. (*includes equity or options).
Name | Company | Catalog Number | Comments |
1 mL syringes | BD | 309628 | |
15 mL conical tubes | Corning | 430052 | |
200 proof ethanol | PharmCo | 111000200 | |
5 mL pipettes | CoStar | 4487 | |
70 micron filter | Fisher | 08-771-2 | |
Accutase | Millipore Sigma | SIG-SCR005 | |
Anased (Xylazine injection, 100 mg/mL) | Covetrus | 33198 | |
Anesthesia System | Patterson Scientific | 78935903 | |
Anesthesic Gas Waste Container | Patterson Scientific | 78909457 | |
Bench protector underpad | Covidien | 10328 | |
C57Bl/6, 6-8 week old mice | Charles River Laboratories | Strain Code 027 | |
ChroMini Pro | Moser | Type 1591-Q | |
Collagenase-Dispase | Roche | #10269638001 | |
Countess II Automated Cell Counter | Thermo Fisher | ||
Countess II FL Hemacytometer | Thermo Fisher | A25750 | |
Debris Removal Solution | Miltenyi Biotech | #130-109-398 | |
D-Luciferin | Goldbio | LUCK-1G | |
DMEM F12 media | Corning | 10-090-CV | |
DMEM media | Corning | 10-013-CV | |
DNAse I | Sigma Aldrich | #10104159001 | |
Eppendorf tubes | Posi-Click | 1149K01 | |
Euthanasia solution | Henry Schein | 71073 | |
FBS | Millipore Sigma | F4135 | |
Fetal Bovine Serum | Thermo Fisher | 10437-028 | |
Formalin | Invitrogen | INV-28906 | |
Gauze | Henry Schein | 101-4336 | |
hEGF | PeproTech EC | 100-15 | |
Heparin | Sigma | H-3149 | |
hFGF-b | PeproTech EC | 1001-18B | |
Induction Chamber | Patterson Scientific | 78933388 | |
Isoflurane | Covetrus | 11695-6777-2 | |
Isoflurane Vaporizer | Patterson Scientific | 78916954 | |
Ketamine | Covetrus | 11695-0703-1 | |
Kopf Stereotactic frame | Kopf Instruments | 5001 | |
Lightfield Microscope | BioTek | Cytation 5 | |
Microinjection Unit | Kopf | 5001 | |
Micromotor drill | Foredom | F210418 | |
MRI system | Bruker | 7T Biospec Avance III MRI Scanner | |
NICO Myriad System | NICO Corporation | ||
Ophthalmic ointment | Puralube vet ointment | ||
Papain | Sigma Aldrich | #P4762 | |
PBS | Invitrogen | #14190250 | |
PenStrep | Millipore Sigma | N1638 | |
Percoll solution | Sigma Aldrich | #P4937 | |
Pipette controller | Falcon | A07260 | |
Povidone-iodine solution | Aplicare | 52380-1905-08 | |
Progesterone | Sigma | P-8783 | |
Putrescine | Sigma | P-5780 | |
RPMI Media | Invitrogen | INV-72400120 | |
Scalpel blade | Covetrus | 7319 | |
Scalpel handle | Fine Science Tools | 91003-12 | |
Skin marker | Time Out | D538,851 | |
Staple remover | MikRon | ACR9MM | |
Stapler | MikRon | ACA9MM | |
Staples | Clay Adams | 427631 | |
Stereotactic Frame | Kopf Instruments | 5000 | |
Sucrose | Sigma Aldrich | S9378 | |
Suture, vicryl 4-0 | Ethicon | J494H | |
T-75 culture flask | Sarstedt | 83-3911-002 | |
TheraPEAKTM ACK Lysing Buffer (1x) | Lonza | BP10-548E | |
Trypsin-EDTA | Corning | MDT-25-053-CI |
Request permission to reuse the text or figures of this JoVE article
Request PermissionExplore More Articles
This article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved